This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
PacBio's (PACB) New Tie-Up to Boost Rare Disease Research
by Zacks Equity Research
PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.
Why You Should Retain Walgreens Boots (WBA) Stock for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Hologic (HOLX) Gains From Core Businesses' Growth, Innovation
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.
Here's Why Investors Should Retain Phibro (PAHC) for Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $81.20, moving +0.2% from the previous trading session.
Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care
by Zacks Equity Research
Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.
3 Reasons to Hold Patterson Companies (PDCO) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
BD's (BDX) Latest Product to Automate Clinical Flow Cytometry
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.
Neogen (NEOG) Introduces Improved Genomic Test for Cats
by Zacks Equity Research
Neogen's (NEOG) My CatScan 2.0 offers insightful genetic information that enables preventive cat care by tackling curable conditions.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.
QIAGEN's (QGEN) QCI Is Used by Danish National Genome Center
by Zacks Equity Research
QIAGEN's (QGEN) QCI Interpret offers evidence-based variant interpretation and reporting, and upholds the highest standards for data security and privacy. It also provides testing sites flexibility.
Here's Why You Should Retain Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) on solid long-term growth potential in the oncology space.
Here's Why You Should Retain Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.
CVS Heath (CVS) MinuteClinic Earns 6th Health Care Approval
by Zacks Equity Research
CVS Heath's (CVS) MinuteClinic has an in-clinic Net Promotor Score of more than 81, putting it in the top customer rankings.
Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
Catalent (CTLT) Tops Q3 Earnings Estimates, Cuts FY23 View
by Zacks Equity Research
Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.
Teleflex's (TFX) Arrow EZ-IO Needle Receives FDA Approval
by Zacks Equity Research
Teleflex's (TFX) Arrow EZ-IO Needle is the first and only intraosseous (IO) needle for MR Conditional labelling.
Bruker (BRKR) Launches ENRICH-iST Kits and Novel Workflow
by Zacks Equity Research
Bruker's (BRKR) ENRICH-iST kit is ready to use right out of the box. The workflow is simple to understand and fully automatable.
Catalent (CTLT) Launches Expanded OneBio Suite to Aid Customers
by Zacks Equity Research
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.